Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is still being studied. It also means that the FDA has not yet approved afatinib for use in patients. In this research study the investigators are looking to see if taking afatinib after surgery works better when taken over a short period of time, compared to a long period of time.

Stanford is now accepting new patients for this trial. Please contact Lisa Zhou at 650-736-4112 for more information.

Investigator(s):

Intervention(s):

  • drug : Afatinib

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Pathologically confirmed diagnosis of non-small cell lung cancer with EGFR mutation - Complete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by AJCC 7th Edition staging criteria - Surgical resection with curative intent was at least 6 months prior to enrollment - At least 3 weeks have passed since completion of adjuvant chemotherapy or radiotherapy

External Links

Explore related trials

Contact information

Primary Contact:

Lisa Zhou 650-736-4112

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: